Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-4375 Injection Receives Notice of Approval for Clinical Trial of Medicinal Products
Hengrui Medicine (600276.SH) announcement, the company's subsidiary Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd. received the national drug...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the approval notice for the clinical trial of SHR-4375 injection from the National Medical Products Administration (referred to as "NMPA"), and will soon start clinical trials.
It is reported that SHR-4375 injection is a biopharmaceutical developed by the company, which can specifically bind to tumor cell surface antigens, kill tumor cells, and is intended for the treatment of advanced malignant solid tumors.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
